Mounjaro to become leading drug by sales in obesity, diabetes market: GlobalData

Mounjaro is expected to achieve an impressive compound annual growth rate of 36 per cent, outpacing Ozempic's 6.5 per cent, over the next seven years. Mounjaro's strong forecast is primarily attributed to its November 2023 FDA approval for obesity, with the US anticipated to be its most lucrative market, accounting for 76 per cent of total sales from 2023 to 2029.